Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO.26 trial of durvalumab + tremelimumab (D+T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).
作者： Harriet Feilotter , Derek J. Jonker , Kimberly Banks , Christopher J. O'Callaghan , Dongsheng Tu
DOI: 10.1200/JCO.2021.39.3_SUPPL.61
关键词: Pembrolizumab 、 Mutation (genetic algorithm) 、 Predictive biomarker 、 Tremelimumab 、 Immunotherapy 、 Durvalumab 、 Colorectal cancer 、 Accelerated approval 、 Oncology 、 Medicine 、 Internal medicine
摘要: 61Background: Pembrolizumab was recently granted tissue agnostic FDA accelerated approval for metastatic cancers with TMB≥10 mut/Mb. However, limited data supports immunotherapy in microsatellite s...
sci-hub.st 参考文章(0)